LifestyleMidday Maryland


Blood Cancer Treatment Options

Posted at 2:32 PM, Mar 23, 2021
and last updated 2021-03-23 14:32:31-04

Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of blood cancer and the most common form of non-Hodgkin lymphoma, accounting for one out of every three cases of NHL diagnosed in the United States.

Previously, an estimated 73% of DLBCL patients will relapse or not respond to treatment, however a new treatment option is giving hope to DLBCL patients.

Breyanzi is a new T cell therapy has been approved by the FDA to treat certain blood cancers.

Learn more about treatment options for lymphoma here.